Association of Surgical Risk With Exogenous Hormone Use in Transgender Patients

    December 2018 in “ JAMA Surgery ”
    Elizabeth R. Boskey, Amir H. Taghinia, Oren Ganor
    Studysummary This systematic review suggests that current evidence does not support routinely discontinuing gender-affirming hormone treatments before surgery, especially testosterone and spironolactone, due to limited data on related perioperative risks.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on archsurg.jamanetwork.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline The Journal of Clinical Endocrinology & Metabolism · 2017

    Related research 2

    1. Association of Surgical Risk With Exogenous Hormone Use in Transgender Patients JAMA Surgery · 2018
    2. Hormonal Treatment of Transgender Women with Oral Estradiol Transgender health · 2018